Related references
Note: Only part of the references are listed.Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors
Fiona Ohlendorf et al.
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
Tristan Ruhwedel et al.
CANCERS (2021)
Inflammation-Based Index and Ga-68-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with Y-90-DOTATOC
Elin Pauwels et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Rudolf A. Werner et al.
MOLECULAR IMAGING AND BIOLOGY (2019)
The Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Study
James R. M. Black et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours
J. Zou et al.
CURRENT ONCOLOGY (2019)
Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG)
Roheena Z. Panni et al.
JOURNAL OF SURGICAL ONCOLOGY (2019)
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Markers of Systemic Inflammatory Response are Prognostic Factors in Patients with Pancreatic Neuroendocrine Tumors (PNETs): A Prospective Analysis
Apostolos Gaitanidis et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma A systematic review and meta-analysis
Li Su et al.
MEDICINE (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer
Garrett L. Jensen et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2017)
Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients
Y. Cho et al.
ANNALS OF ONCOLOGY (2016)
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up
Dieter Hoersch et al.
EUROPEAN JOURNAL OF CANCER (2016)
C-Reactive Protein as a New Prognostic Factor for Survival in Patients With Pancreatic Neuroendocrine Neoplasia
Dominik Wiese et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Preoperative Leukocytosis in Colorectal Cancer Patients
Zhobin Moghadamyeghaneh et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2015)
Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact
Zhen Su et al.
PLOS ONE (2015)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (vol 40, pg 800, 2013)
L. Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer
Jian L. Campian et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification
Irina Velikyan et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Uterine Cervical Cancer Displaying Tumor-Related Leukocytosis: A Distinct Clinical Entity With Radioresistant Feature
Seiji Mabuchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
MRI volume measurements compared with the RECIST 1.1 for evaluating the response to neoadjuvant chemotherapy for mass-type lesions
Yeong Yi An et al.
BREAST CANCER (2014)
Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?
M. Oe. Oeksuez et al.
DIAGNOSTIC AND INTERVENTIONAL IMAGING (2014)
Preoperative Leukocytosis Imposes an Increased Risk of Recurrence and Death Among Patients With Nonendometrioid Endometrial Carcinoma
Michael J. Worley et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor
Yin Wu et al.
DIAGNOSTICS (2013)
Effect of Tumor Heterogeneity on the Assessment of Ki67 Labeling Index in Well-differentiated Neuroendocrine Tumors Metastatic to the Liver: Implications for Prognostic Stratification
Zhaohai Yang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy
Samer Ezziddin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Samer Ezziddin et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Dik J. Kwekkeboom et al.
ENDOCRINE-RELATED CANCER (2010)
Immune infiltration in human tumors: a prognostic factor that should not be ignored
F. Pages et al.
ONCOGENE (2010)
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Francesco Colotta et al.
CARCINOGENESIS (2009)
68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
Michael Gabriel et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Radiologic measurements of tumor response to treatment:: Practical approaches and limitations
Chikako Suzuki et al.
RADIOGRAPHICS (2008)
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2
Andrew T. Chan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene
MG Borrello et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
IL-1 is required for tumor invasiveness and angiogenesis
E Voronov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
